CEL-SCI Corporation (CVM)
| Market Cap | 26.03M -60.3% |
| Revenue (ttm) | n/a |
| Net Income | -22.70M |
| EPS | -2.57 |
| Shares Out | 17.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,443 |
| Open | 1.400 |
| Previous Close | 1.380 |
| Day's Range | 1.370 - 1.500 |
| 52-Week Range | 0.890 - 13.477 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 12.50 (+744.6%) |
| Earnings Date | Aug 17, 2026 |
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections,... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CVM stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 744.60% from the latest price.
News
CEL-SCI reports Q3 EPS (47c) vs ($1.36) last year
“This was a quarter of important progress across our clinical, regulatory and commercialization programs as we move Multikine closer to patients,” stated CEL-SCI (CVM) CEO Geert Kersten. “Our recently...
CEL-SCI Reports Fiscal Third Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
CEL-SCI announces publication of study supporting multikine biomarker strategy
CEL-SCI (CVM) announced the publication of its study, “A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients with Low Tumor PD-L1 Expression: The IT-MATTERS Clini...
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.
CEL-SCI announces manuscript on Phase 3 study to be published in Oral Oncology
CEL-SCI (CVM) announced that a manuscript highlighting the latest findings from its Phase 3 study titled “A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients wi...
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.
CEL-SCI to launch FDA registration-enabling Phase 3 Confirmatory study
CEL-SCI (CVM) Corporation announced it is launching its global Confirmatory Registration Study of Multikine as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally ad...
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.
CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026
CEL-SCI (CVM) announced the successful conclusion of a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 on June 22nd in San Diego. Under the agreement, Amarox…
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.
CEL-SCI Announces Closing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.
CEL-SCI highlights dual-track strategy for Multikine
CEL-SCI (CVM) highlighted its dual-track strategy to bring Multikine to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saud...
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.
CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
CEL-SCI, Saudi Amarox to conduct signing ceremony for strategic agreement
CEL-SCI (CVM) Corporation announced it will participate in a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego, California. The ceremony will mark a…
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.
CEL-SCI reports Q2 EPS (67c) vs. ($2.33) last year
“During the fiscal second quarter, we made significant progress advancing Multikine toward potential commercialization and regulatory approval in multiple markets,” stated CEL-SCI (CVM) CEO Geert Kers...
CEL-SCI Reports Fiscal Second Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.
CEL-SCI 6M share Secondary priced at $1.20
ThinkEquity acted as sole book running manager for the offering.
CEL-SCI Corporation Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.
CEL-SCI enters strategic agreement with Amarox over Multikine distribution
CEL-SCI (CVM) announced it has signed a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine in...
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.
CEL-SCI files to sell 3.44M shares of common stock
ThinkEquity is acting as the exclusive placement agent in connection with this offering.
CEL-SCI Reports Fiscal First Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.